[The new effective anticestodian agent fluxane].
Trusov
S N
SN
Mikhaĭlitsyn
F S
FS
Sevbo
D P
DP
Arkhipov
I A
IA
Koveshnikova
E I
EI
D000284:Administration, Oral; D000818:Animals; D000923:Anticestodal Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D001549:Benzamides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D052160:Benzothiazoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D002589:Cestoda / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D006925:Hymenolepiasis / Q000188:drug therapy*; D048189:Hymenolepis nana; D051379:Mice; D008989:Monieziasis / Q000188:drug therapy*; D012756:Sheep; D012757:Sheep Diseases / Q000188:drug therapy*
D000923:Anticestodal Agents; D001549:Benzamides; D052160:Benzothiazoles; C512400:N-(((2-benzothiazolyl)thio)-5-(trifluoromethyl)phenyl)-2-hydroxy-3,5-dibromobenzamide